{
    "clinical_study": {
        "@rank": "11577", 
        "arm_group": [
            {
                "arm_group_label": "Repetitive TMS", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:\nFrequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
            }, 
            {
                "arm_group_label": "Sham TMS", 
                "arm_group_type": "Sham Comparator", 
                "description": "Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain."
            }
        ], 
        "brief_summary": {
            "textblock": "We aim to evaluate the safety and efficacy of repetitive transcranial magnetic stimulation\n      (rTMS) for apathy treatment in patients with Alzheimer's disease (AD). We hypothesize that\n      rTMS will be superior to placebo to reduce apathy symptoms and severity in patients with AD."
        }, 
        "brief_title": "Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alzheimer's Disease", 
            "Apathy"
        ], 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "This study aims to enroll 40 patients with mild and moderate Alzheimer's disease with apathy\n      symptoms that will be randomized to receive rTMS or sham procedure. Subjects will be\n      randomized in two arms (rTMS or sham procedure) in 1:1 proportion.\n\n      Eligibility criteria:\n\n        -  Diagnosis of Alzheimer's disease, mild and moderate stage (MMSE range from 10 to 20);\n\n        -  Diagnosis of apathy;\n\n        -  age between 60 and 85 years-old;\n\n        -  On stable doses of cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or\n           memantine for at least 6 months prior to enrollment;\n\n      The primary outcome measures is the Apathy Inventoire. Secondary outcome measures are the\n      NPI score, ADAS-cog scores and the Zarit Burden Scale scores."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 60 to 85 years-old\n\n          -  Mild or moderate Alzheimer's disease (MMSE scores between 10 and 20)\n\n          -  Apathy diagnosis\n\n          -  On stable doses of cholinesterase inhibitors (donepezil, galantamine, rivastigmine)\n             and/or memantine for at least 6 months prior to enrollment\n\n        Exclusion Criteria:\n\n          -  history of epilepsy or convulsions\n\n          -  History of migraine or headaches episodes twice per week or more\n\n          -  History of neurodegenerative diseases other than Alzheimer's disease\n\n          -  Current use of first generation antipsychotics, clozapine, tricyclic drugs or\n             anticonvulsants\n\n          -  History of cerebral ischemic episode"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885806", 
            "org_study_id": "CAAE: 15388913.6.0000.5149"
        }, 
        "intervention": [
            {
                "arm_group_label": "Repetitive TMS", 
                "description": "All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freq\u00fcency: 10 Hz Intensity: 90% limiar motor Session duration:  16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex", 
                "intervention_name": "Magnetic Stimulator Magstim Rapid 2", 
                "intervention_type": "Device", 
                "other_name": "rTMS"
            }, 
            {
                "arm_group_label": "Sham TMS", 
                "description": "This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.\nTotal of session: 10", 
                "intervention_name": "Sham  Magnetic Stimulator", 
                "intervention_type": "Device", 
                "other_name": "Sham"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Apathy; Alzheimer's disease; Cognition; Burden of Care", 
        "lastchanged_date": "June 24, 2013", 
        "location": [
            {
                "contact": {
                    "email": "romanosilva@gmail.com", 
                    "last_name": "Marco A Romano-Silva, MD, PhD", 
                    "phone": "+55 31 3409-9758"
                }, 
                "facility": {
                    "address": {
                        "city": "Belo Horizonte", 
                        "country": "Brazil", 
                        "state": "Outside of U.S.", 
                        "zip": "30130-100"
                    }, 
                    "name": "Federal University of Minas Gerais"
                }, 
                "investigator": {
                    "last_name": "Breno S Diniz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "romanosilva@gmail.com", 
                    "last_name": "Marco A Romano-Silva, MD, PhD", 
                    "phone": "+55 31 3409-9785"
                }, 
                "facility": {
                    "address": {
                        "city": "Belo Horizonte", 
                        "country": "Brazil", 
                        "state": "Outside of U.S.", 
                        "zip": "30130-100"
                    }, 
                    "name": "Federal University of Minas Gerais"
                }, 
                "investigator": {
                    "last_name": "Breno S Diniz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study", 
        "other_outcome": {
            "description": "Assessment of rTMS safety by the UKU scale.", 
            "measure": "Safety assessment", 
            "safety_issue": "Yes", 
            "time_frame": "4th week, 8th week, 12th week"
        }, 
        "overall_contact": {
            "email": "brenosatler@gmail.com", 
            "last_name": "Breno S Diniz, MD, PhD", 
            "phone": "+55 31 97950860"
        }, 
        "overall_official": {
            "affiliation": "Federal University of Minas Gerais", 
            "last_name": "Breno S Diniz, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction of 30% in the Apathy Inventoire scores between baseline and 12 weeks after treatment.", 
            "measure": "Change in apathy symptoms", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885806"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of Minas Gerais", 
            "investigator_full_name": "Breno Satler de Oliveira Diniz", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Improvement in ADAS-Cog scores between baseline and 12 weeks after treatment.", 
                "measure": "Change in ADAS-Cog scores", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Reduction in the Zarit Burden Scale between baseline and 12 weeks after treatment.", 
                "measure": "Change in the Zarit Burden Scale", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Federal University of Minas Gerais", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Federal University of Minas Gerais", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}